LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Home・Aandelen Lijst・MacroGenics Inc

MacroGenics Inc

Gesloten

SectorGezondheidszorg

4.21 1.94

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

4.03

Max

4.34

Belangrijke statistieken
By Trading Economics
Inkomsten	-31M -14M
Verkoop	-32M 41M
EPS	-0.22
Winstmarge	-34.333
Werknemers	293
EBITDA	-37M -15M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+83.48% upside

Dividenden
By Dow Jones
Volgende Winsten	19 mei 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	65M 188M
Vorige openingsprijs	2.27
Vorige sluitingsprijs	4.21

Nieuwssentiment

By Acuity

35%

65%

112 / 346 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Neutral Evidence

1.47 / 1.64 Steun & Weerstand

MacroGenics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

14 mei 2026, 22:44 UTC

Acquisities, Fusies, Overnames

LVMH to Sell Marc Jacobs Fashion Brand to WHP, G-III Apparel -- 2nd Update

14 mei 2026, 22:27 UTC

Acquisities, Fusies, Overnames

LVMH Selling Marc Jacobs Fashion Brand to WHP, G-III Apparel -- Update

14 mei 2026, 22:12 UTC

Winsten

Applied Materials Raises Outlook as Semiconductor Equipment Demand Grows -- 2nd Update

14 mei 2026, 21:52 UTC

Acquisities, Fusies, Overnames

LVMH to Sell Marc Jacobs

15 mei 2026, 00:00 UTC

Winsten

Honda's Never Faced a Crisis Like This -- And a Comeback Won't Be Easy -- WSJ

14 mei 2026, 23:57 UTC

Acquisities, Fusies, Overnames

Kakao: Stake Sales Aim to Secure Funds for Future Investments

14 mei 2026, 23:56 UTC

Acquisities, Fusies, Overnames

Kakao: Share Sale to Lower Kakao Investment's Stake in Dunmau to 4.03%

14 mei 2026, 23:56 UTC

Acquisities, Fusies, Overnames

Kakao: Affiliate Kakao Investment to Sell 2.3M Dunamu Shares on June 15

14 mei 2026, 23:56 UTC

Marktinformatie

Gold Prices Rise on Strong Demand -- Market Talk

14 mei 2026, 23:56 UTC

Acquisities, Fusies, Overnames

Kakao to Sell 6.55% Stake in Crypto Exchange Operator Dunamu to Hana Financial for KRW1.003T

14 mei 2026, 23:50 UTC

Marktinformatie

Global Equities Roundup: Market Talk

14 mei 2026, 23:50 UTC

Marktinformatie

Nikkei May Rise as AI Enthusiasm Continues -- Market Talk

14 mei 2026, 23:47 UTC

Winsten

JSW Steel: Prolonged Supply-Chain Disruptions Due to Middle East Crisis Pose Risk to Growth >500228.BY

14 mei 2026, 23:47 UTC

Winsten

JSW Steel Results Supported by Higher Steel Prices, One-Off Divestment Gains >500228.BY

14 mei 2026, 23:46 UTC

Winsten

JSW Steel 4Q Net INR163.7B Vs. Net INR21.39B >500228.BY

14 mei 2026, 23:46 UTC

Winsten

JSW Steel 4Q Rev INR511.8B Vs. INR448.19B >500228.BY

14 mei 2026, 23:28 UTC

Marktinformatie

New Zealand's Economy Faltering Amid Shocks -- Market Talk

14 mei 2026, 23:00 UTC

Marktinformatie

Australia's One Nation Party Leads In The Polls -- Market Talk

14 mei 2026, 22:46 UTC

Marktinformatie

Global Equities Roundup: Market Talk

14 mei 2026, 22:46 UTC

Marktinformatie

Court Decision 'Negative But Balanced' for Coles -- Market Talk

14 mei 2026, 22:46 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

14 mei 2026, 22:35 UTC

Marktinformatie

Fed's Warsh Talks Big Game; Will Focus On Credibility First -- Market Talk

14 mei 2026, 22:11 UTC

Acquisities, Fusies, Overnames

LVMH Agrees to Sell Marc Jacobs -- WSJ

14 mei 2026, 22:06 UTC

Marktinformatie

Applied Materials Gets Improved Visibility into Customer Orders -- Market Talk

14 mei 2026, 22:04 UTC

Winsten

Thai Beverage Results Supported by Higher Contributions From Spritis Business >Y92.SG

14 mei 2026, 22:04 UTC

Winsten

Thai Beverage 2Q Net THB7.37B Vs. Net THB6.74B >Y92.SG

14 mei 2026, 22:04 UTC

Winsten

Thai Beverage 2Q Rev THB86.52B Vs. THB85.35B >Y92.SG

14 mei 2026, 22:00 UTC

Winsten

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

14 mei 2026, 21:55 UTC

Winsten

Nu Holdings 1Q EPS 18c >NU

14 mei 2026, 21:55 UTC

Winsten

Nu Holdings 1Q Rev $4.97B >NU

Peer Vergelijking

Prijswijziging

MacroGenics Inc Prognose

Koersdoel

By TipRanks

83.48% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 6.33 USD 83.48%

Hoogste 9 USD

Laagste 4 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor MacroGenics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

5 ratings

Buy

Hold

Sell

Gebaseerd op 5 analisten die aandelenratings hebben gegeven aan MacroGenics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

1.47 / 1.64Steun & Weerstand

The bullish and bearish events are balanced.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

112 / 346 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over MacroGenics Inc

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.